Theratechnologies (THTX) announced the availability of EGRIFTA WR for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WR by the U.S. Food and Drug Administration, FDA, earlier this year. The new formulation of tesamorelin for injection will gradually replace EGRIFTA SV, the current formulation. Specialty pharmacies are now ordering EGRIFTA WR to fill prescriptions for the new formulation. EGRIFTA SV will continue to be available during a transitional period as managed care plans increasingly provide coverage for EGRIFTA WR.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies Gains Support for Future Pak Acquisition
- Theratechnologies says ISS, Glass Lewis recommend vote ‘FOR’ Future Pak plan
- Theratechnologies Announces Acquisition by CB Biotechnology with Significant Shareholder Premium
- Theratechnologies receives interim order in acquisition by CB Biotechnology
- Theratechnologies’ Ibalizumab Study: A Potential Game-Changer for Multidrug-Resistant HIV